Table 3.
Multivariate Cox regression analysis of KLK mRNA expression levels in advanced high-grade serous ovarian cancer
| Clinical parameters | PFS | OS | ||||
|---|---|---|---|---|---|---|
| No.a | HR (95% CI)b | p | No.a | HR (95% CI)b | p | |
| Age | 0.592 | 0.660 | ||||
| ≤ 60 years | 41 | 1 | 46 | 1 | ||
| > 60 years | 57 | 0.87 (0.53–1.44) | 63 | 1.13 (0.65–1.96) | ||
| Residual tumor mass | 0.005 | < 0.001 | ||||
| 0 mm | 57 | 1 | 59 | 1 | ||
| > 0 mm | 41 | 2.20 (1.27–3.81) | 50 | 3.29 (1.69–6.41) | ||
| Ascites fluid volume | 0.363 | 0.605 | ||||
| ≤ 500 ml | 60 | 1 | 64 | 1 | ||
| > 500 ml | 38 | 1.33 (0.76–2.31) | 45 | 1.18 (0.63–2.20) | ||
| KLK7 mRNAc | 0.010 | 0.041 | ||||
| low | 72 | 1 | 80 | 1 | ||
| high | 26 | 2.14 (1.20–3.82) | 29 | 1.89 (1.03–3.49) | ||
| KLK5 + KLK7 mRNAd | 0.067 | 0.313 | ||||
| low | 51 | 1 | 59 | 1 | ||
| high | 47 | 1.59 (0.97–2.61) | 50 | 1.33 (0.76–2.31) | ||
Chi-square test, significant p-values (p ≤ 0.05) are indicated in bold, trends towards significance (p ≤ 0.08) in italics.
aNumber of patients
bHR hazard ratio (CI confidence interval) of multivariate Cox regression analysis
cDichotomized into low and high levels by the 67th percentile
dDichotomized into low level by KLK5 low and KLK7 low, and high level by KLK5 high and/or KLK7 high; cut-off point: KLK5 = 67th percentile, KLK7 = 67th percentile